Recent News

Use of Ibrutinib During COVID-19–Induced Respiratory Failure in CLL: Case Study

Novel Mutation and CLL Resistance to BTK and SYK Inhibition: Case Study

Exploring Rapid Dose Escalation of Venetoclax in Patients With CLL

Personalizing Management of CLL: From the Advanced Practitioner Perspective

Can LCK Deletion Result in Acceleration of CLL?

Comparing Front-Line Treatments in CLL: Focus on Acalabrutinib

Adding Zanubrutinib to Obinutuzumab in CLL

Early Use of Lenalidomide With Pneumococcal Vaccine for High-Risk CLL

Genetic Landscape of CLL With IGH Translocations

SOHO 2020: Link Between WNT3 and LEF1 Expression Levels and Survival in CLL?

SOHO 2020: Interim Analysis of Real-World Registry of Elderly Patients With CLL

Managing CLL in the Era of COVID-19: Guidance From Global Experts

SOHO 2020: Debulking Regimens Prior to Venetoclax Therapy for CLL

SOHO 2020: Chemotherapy-Free Combination Therapy for CLL Under Study in Phase III Trial

Bendamustine Plus Rituximab in Older Patients With CLL: Swedish Real-World Study

Chemoimmunotherapy Regimen Under Study in Younger Patients With CLL

Case Report of Breast Involvement in a Male Patient With CLL

High-Risk CLL: Hematopoietic Stem Cell Transplantation Followed by Immune Intervention

Study Shows Benefit of Novel Agents for CLL With 17p Deletion

CLL and COVID-19: Large Italian Survey on Changes in Management

Case Report Features Potential Link Between JAK2 Inhibition and CLL

CLL and COVID-19: Treatment Lessons Learned

CLL and COVID-19: Continuity of Care in Italian Tertiary Hospital

FDA Clearance Granted for Assay for Monitoring Minimal Residual Disease in CLL

Dual PI3Kδ/CK1ε Inhibition on CLL T Cells

Predictors of Outcome in Patients with CLL and COVID-19

Can Prognosis Assessments Accurately Predict Time to First Treatment in Early-Stage CLL?

CLL and COVID-19: When May Humoral Immunity Therapy Be Indicated?

Zanubrutinib for Resistant CLL and Small Lymphocytic Lymphoma

Two Decades of Data Confirm Poor Prognosis With Richter Transformation in CLL

EHA25 Virtual: Quality of Life With Duvelisib Versus Ofatumumab in CLL

EHA25 Virtual: Does Administration Sequence of Ibrutinib/Obinutuzumab in CLL Affect Toxicity?

Real-World Study Finds VHA Adopts Novel Agents in CLL Treatment

AACR II: Linking HPV Infection to Skin Cancer in Patients With CLL

EHA25 Virtual: First-Line Ibrutinib/Venetoclax Combination in CLL

EHA25 Virtual: Trial Update on Ibrutinib Plus Umbralisib in Resistant CLL

ASCO20: Venetoclax Plus Obinutuzumab in Treatment-Naive CLL

EHA25 Virtual: Long-Term Results With Acalabrutinib in Treatment-Naive CLL

ASCO20: Final Results From GENUINE Trial of Ublituximab Plus Ibrutinib in CLL

EHA25 Virtual: VENICE-I Findings With Venetoclax in Resistant CLL

EHA25 Virtual: Phase III Trial to Study Acalabrutinib-Based Combination in CLL

ASCO20: Does Early Discontinuation of Venetoclax Affect Outcomes in CLL?

ASCO20: Cirmtuzumab Plus Ibrutinib in Relapsed or Refractory CLL

ASCO20: Final Results From ASCEND Trial of Acalabrutinib in Resistant CLL

ASCO20: Intermittent Scheduling of PI3Kδ Inhibitor in CLL